Spruce Biosciences (SPRB) Change in Accured Expenses (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Change in Accured Expenses of -$1.3 million for Q1 2026, down 1028.57% year-over-year from $140000.0 in Q1 2025, and down 132.56% quarter-over-quarter from $4.0 million in Q4 2025.
Spruce Biosciences (SPRB) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Change in Accured Expenses for 8 consecutive years, with -$1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 1028.57% year-over-year to -$1.3 million; the TTM figure through Mar 2026 stood at -$1.8 million (down 4083.33% YoY), while the FY2025 annual figure was -$317000.0, down 33.76% from the prior year.
- Change in Accured Expenses fell to -$1.3 million in Q1 2026 per SPRB's latest filing, from $4.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $4.0 million in Q4 2025 and bottomed at -$3.9 million in Q3 2025.
- Historically, Change in Accured Expenses has averaged -$138882.4 across 5 years, with a median of -$64000.0 in 2024.
- On a YoY basis, Change in Accured Expenses climbed as much as 6339.06% in 2025 and fell as far as 6353.33% in 2025.
- Spruce Biosciences' Change in Accured Expenses stood at -$102000.0 in 2022, then soared by 52.94% to -$48000.0 in 2023, then plunged by 33.33% to -$64000.0 in 2024, then soared by 6339.06% to $4.0 million in 2025, then tumbled by 132.56% to -$1.3 million in 2026.
- Business Quant data shows SPRB's Change in Accured Expenses at -$1.3 million in Q1 2026, $4.0 million in Q4 2025, and -$3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | -589,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -589,000.00 |
| Jun 30, 2026 | -589,000.00 |
| Mar 31, 2026 | -1.30 Mn |
| Mar 31, 2026 | -1.30 Mn |
| Dec 31, 2025 | 3.99 Mn |
| Dec 31, 2025 | 3.99 Mn |
| Sep 30, 2025 | -3.87 Mn |
| Sep 30, 2025 | -3.87 Mn |
| Jun 30, 2025 | -578,000.00 |
| Jun 30, 2025 | -578,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Dec 31, 2024 | -64,000.00 |
| Dec 31, 2024 | -64,000.00 |
| Sep 30, 2024 | -60,000.00 |
| Sep 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -58,000.00 |
| Jun 30, 2024 | -58,000.00 |
| Mar 31, 2024 | -55,000.00 |
| Mar 31, 2024 | -55,000.00 |